Description: This report is presented in the form of a Tableau dashboard and is the sixth public release from this report series and contains the results of an excess mortality analysis for the fourth quarter of 2021. Data from 30 companies representing approximately 69% of the industry’s face amount inforce were included in the analyses in this report. A total of 3.2 million death claims from individual life policies from 2015 through December 31, 2021 make up the basis of the analyses. The report also compares the experience under COVID-19 of the insured population versus the general population.

Description: LIMRA, Reinsurance Group of America (RGA), the Society of Actuaries (SOA) Research Institute, and TAI have collaborated on an ongoing effort to analyze the impact of COVID-19 on the individual life insurance industry’s mortality experience and share the emerging results with the insurance industry and the public. This report documents a high-level analysis of the claims that have been reported.

Description: Deaths due to non-medical causes such as drug overdoses, alcohol-related deaths, homicides, suicides and accidents are the leading cause of death for those under the age of 50 in the U.S. and is the fourth leading cause of death (after cardiovascular, cancer and COVID-19) for all ages combined in 2021. Take a deep dive with us into the mortality trends for non-medical causes of death and the impact these deaths have on different types of life insurance, including simplified issued, fully underwritten and group.

Description: Mortality improvement assumptions have typically been focused on all-cause mortality improvement. However, as evidenced in recent years, the cause of death has a large impact on mortality improvement. Join our panel of experts as they discuss mortality improvement through the lens of different causes of death. This discussion will include a review of the historical cause specific mortality improvement trends seen in the U.S. population and how this relates to the insured population. The panelists will then discuss how to use these trends to inform future mortality improvement assumptions. Key learning objectives include: - Identifying the trends in mortality improvement for select causes of death - Understanding how to adapt these for an insured population - Applying these learnings to mortality improvement assumptions

Description: In this wide-ranging session, expect updates on the work of the Individual Life Experience Committee and delve into some interesting recent research. You'll gain an update on recent findings from the Individual Life Experience Committee regarding individual life mortality experience.

Description: Focus on Accelerated Underwriting (AUW) in the life insurance industry, which is an expedited underwriting process that utilizes predictive models. Expect to address the challenges in designing the process, from modelling to performance monitoring. Additionally, you'll address risk management, particularly in mortality and proxy discrimination andhighlight the role an actuary can play in the AUW process, as well aswhat they should know to contribute effectively.

Description: Discuss population mortality improvement trends in the U.S. This will include analysis of cause of death data and trends in mortality pre-pandemic and during the pandemic. We will also discuss ways to think about translating population mortality improvement to an insured population.Learning outcomes includea better understanding of the drivers of recent mortality improvement and insights on how to create a company view on mortality improvement.

Description: This session will explore the mortality implications of reaching new markets, leveraging unique analysis that directly compares the mortality experience of the general populations and insured populations. Experts will explore how the industry can responsibility reduce the insurance gap, effectively employ digital data to assess new markets, and tackle the challenge with eyes wide open. At the conclusion of the session, attendees will be able to: •Understand differences in mortality experience between various populations – general, insured and uninsured •Articulate the challenges the industry may face in closing the insurance gap •Appreciate the role digital evidence can play in managing and accessing new marketing segments

Description: This session guides actuaries through the key steps of building a principles-based valuation model for a life product, starting with a brief overview of key requirements in LDTI and VM-20. The focus is on practical steps: defining product specs, sourcing in-force data, gathering actuarial assumptions and incorporating economic scenarios. We'll walk through a simple term life example, prioritizing Day 1 essentials such as accurate cash flow projections and basic reserve calculations. Attendees will learn where to find critical inputs (e.g., IT for data, pricing teams for specs), how to structure a model and pitfalls to avoid. Participants will gain foundational skills to construct LDTI and VM-20 models, confidence in prioritizing model build phases and a clear starting point for sourcing inputs.